bioAffinity Technologies, Inc. (BIAF)
USD 1.04
(1.96%)
USD 1.04
(1.96%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 8.76 Million USD | 112.07% |
| 2022 | 4.01 Million USD | 81.95% |
| 2021 | 2.2 Million USD | -15.27% |
| 2020 | 2.6 Million USD | -14.67% |
| 2019 | 3.05 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 2.92 Million USD | 17.09% |
| 2024 Q1 | 2.62 Million USD | -4.14% |
| 2023 Q2 | 1.79 Million USD | 15.27% |
| 2023 FY | 8.51 Million USD | 112.07% |
| 2023 Q4 | 2.74 Million USD | 12.22% |
| 2023 Q3 | 2.44 Million USD | 35.99% |
| 2023 Q1 | 1.55 Million USD | -4.13% |
| 2022 Q2 | 685.28 Thousand USD | -5.74% |
| 2022 Q1 | 727.04 Thousand USD | 10.2% |
| 2022 FY | 4.01 Million USD | 81.95% |
| 2022 Q4 | 1.62 Million USD | 66.39% |
| 2022 Q3 | 977.16 Thousand USD | 42.59% |
| 2021 Q3 | 526.29 Thousand USD | -0.62% |
| 2021 FY | 2.2 Million USD | -15.27% |
| 2021 Q4 | 659.75 Thousand USD | 25.36% |
| 2021 Q1 | 491.2 Thousand USD | -75.8% |
| 2021 Q2 | 529.56 Thousand USD | 7.81% |
| 2020 FY | 2.6 Million USD | -14.67% |
| 2020 Q4 | 2.02 Million USD | 0.0% |
| 2019 FY | 3.05 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bionano Genomics, Inc. | 148.99 Million USD | 94.117% |
| Prenetics Global Limited | 60.73 Million USD | 85.569% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 46.135% |
| CareDx, Inc | 277.76 Million USD | 96.845% |
| Exact Sciences Corporation | 2.06 Billion USD | 99.575% |
| Exagen Inc. | 52.29 Million USD | 83.239% |
| Inotiv, Inc. | 246.9 Million USD | 96.45% |
| Guardant Health, Inc. | 901.62 Million USD | 99.028% |
| Biodesix, Inc. | 77.41 Million USD | 88.679% |
| BioNexus Gene Lab Corp. | 3.92 Million USD | -123.417% |
| Precipio, Inc. | 13.63 Million USD | 35.732% |
| iSpecimen Inc. | 16.27 Million USD | 46.153% |
| Natera, Inc. | 938.98 Million USD | 99.067% |
| Aspira Women's Health Inc. | 24.11 Million USD | 63.652% |
| Standard BioTools Inc. | 113.48 Million USD | 92.277% |
| 23andMe Holding Co. | 420.73 Million USD | 97.917% |
| Castle Biosciences, Inc. | 242.78 Million USD | 96.39% |
| Personalis, Inc. | 128.14 Million USD | 93.16% |
| Aclaris Therapeutics, Inc. | 110.52 Million USD | 92.07% |
| Applied DNA Sciences, Inc. | 16.48 Million USD | 46.837% |
| OpGen, Inc. | 30.65 Million USD | 71.411% |
| T2 Biosystems, Inc. | 41.49 Million USD | 78.877% |
| Myriad Genetics, Inc. | 600.1 Million USD | 98.539% |
| ICON Public Limited Company | 755.64 Million USD | 98.84% |
| NeoGenomics, Inc. | 341.25 Million USD | 97.432% |
| Star Equity Holdings, Inc. | 16.27 Million USD | 46.135% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 99.198% |
| RadNet, Inc. | 268.87 Million USD | 96.74% |
| MDxHealth SA | 71.25 Million USD | 87.7% |
| Psychemedics Corporation | 11.33 Million USD | 22.668% |
| Illumina, Inc. | 3.81 Billion USD | 99.77% |
| Check-Cap Ltd. | 19.28 Million USD | 54.556% |
| Twist Bioscience Corporation | 354.18 Million USD | 97.525% |
| DarioHealth Corp. | 62.17 Million USD | 85.902% |
| Fulgent Genetics, Inc. | 171.9 Million USD | 94.901% |
| Sera Prognostics, Inc. | 39.91 Million USD | 78.042% |
| ENDRA Life Sciences Inc. | 10.52 Million USD | 16.69% |
| OPKO Health, Inc. | 574.68 Million USD | 98.475% |
| Medpace Holdings, Inc. | 187.68 Million USD | 95.33% |
| Neogen Corporation | 405.23 Million USD | 97.837% |
| Intelligent Bio Solutions Inc. | 11.7 Million USD | 25.143% |
| Prenetics Global Limited | 60.73 Million USD | 85.569% |
| Mainz Biomed B.V. | 27.15 Million USD | 67.722% |
| Trinity Biotech plc | 46.49 Million USD | 81.149% |
| Neuronetics, Inc. | 82.25 Million USD | 89.345% |
| Sotera Health Company | 300.46 Million USD | 97.083% |
| bioAffinity Technologies, Inc. | 8.76 Million USD | 0.0% |